Huttner Kenneth 4
4 · LogicBio Therapeutics, Inc. · Filed Feb 22, 2019
Insider Transaction Report
Form 4
Huttner Kenneth
SVP, Head of Clinical Dev.
Transactions
- Award
Stock Option (right to buy)
2019-02-20+50,818→ 50,818 totalExercise: $9.06Exp: 2029-02-19→ Common Stock (50,818 underlying)
Footnotes (1)
- [F1]The option will vest as to 25% of the shares on the first anniversary of the grant date and in equal monthly installments over the next three years.